TOMI's SteraMist Gains Traction Amid Global Norovirus and Ebola Surges
Event summary
- TOMI highlights rising demand for SteraMist technology amid global norovirus outbreaks and Ebola emergencies.
- Norovirus surges persist into late spring, impacting hikers and cruise ships, with over 100 cases on the Caribbean Princess.
- SteraMist's ionized Hydrogen Peroxide (iHP) technology is validated for norovirus contamination control in high-traffic industries.
- TOMI supports medical transport groups and Regional Emerging Special Pathogen Treatment Centers (RESPTCs) for high-consequence containment.
- CEO Dr. Halden Shane emphasizes the need for automated, high-level disinfection technology in modern infectious disease preparedness.
The big picture
TOMI's SteraMist technology is gaining strategic relevance as global health organizations report increased infectious disease alerts, from norovirus surges to Ebola emergencies. The company's position as a leader in disinfection solutions aligns with a broader industry shift toward automated, high-level biosecurity measures. With support from the U.S. Department of Defense and validation across multiple high-traffic sectors, TOMI is well-positioned to capitalize on the long-term demand cycle for advanced infection-control technologies.
What we're watching
- Technology Adoption
- How the pace of SteraMist adoption will accelerate across high-traffic industries amid rising disease threats.
- Market Positioning
- Whether TOMI can sustain its leadership in environmental decontamination as global biosecurity spending expands.
- Regulatory Influence
- The extent to which WHO and CDC alerts will drive institutional investments in advanced infection-control technologies.